Bronholitin - instructions for use. Bronholitin: instructions for use and what it is needed for, price, reviews, analogues Bronholitin capsules

P N016176/01

Trade name of the drug:

Bronholitin®

Group name:

Glaucine + Ephedrine

Dosage form:

syrup.

Composition Bronholitin® syrup

5 ml of syrup contains:

active substances: glaucine hydrobromide - 5.75 mg, ephedrine hydrochloride - 4.60 mg;

Excipients: basil oil (5.75 mg), citric acid monohydrate (2.99 mg), sucrose (2012.00 mg), methyl parahydroxybenzoate (6.90 mg), propyl parahydroxybenzoate (1.15 mg), polysorbate 80 (57.50 mg), ethanol 96% (1.7 vol.%) (69.0 mg), purified water (up to 5.0 ml).

Description Broncholitin® syrup

A thick liquid from transparent to slightly opalescent, from light yellow to yellow-green or light brown in color with a specific odor.

Pharmacotherapeutic group:

combined antitussive agent (central-acting antitussive agent + sympathomimetic agent).

Code ATX:

Pharmacological properties

Pharmacodynamics

Bronholitin® is a combined drug with a pronounced antitussive and bronchodilator effect.

Glaucine suppresses the cough center without leading to respiratory depression, constipation or drug dependence. It has a weak bronchodilator effect. Ephedrine is an indirect adrenergic agonist (suppresses the activity of amino oxidase), and also has a weak stimulating effect directly on adrenergic receptors. Causes the release of norepinephrine and adrenaline, has an antispasmodic effect on the smooth muscles of the bronchi, stimulates the respiratory center and, due to its vasoconstrictive effect, reduces swelling of the bronchial mucosa.

Pharmacokinetics

After oral administration, glaucine and ephedrine quickly and

completely absorbed from the gastrointestinal tract. The maximum plasma concentration of glaucine is achieved 1.5 hours after its administration.

Ephedrine is distributed in the body with accumulation mainly in the liver, lungs, kidneys, spleen and brain. Glaucine and ephedrine (small part) are metabolized in the liver.

Glaucine is excreted in the urine in the form of metabolites and unchanged.

The half-life of ephedrine is approximately 3-6 hours. Eliminated in urine mainly unchanged.

Indications for use Broncholitin® syrup

In the complex treatment of diseases of the respiratory system accompanied by a dry cough: acute inflammatory diseases of the upper respiratory tract, acute and chronic bronchitis, tracheobronchitis, COPD, bronchial asthma, pneumonia, whooping cough.

Contraindications

Hypersensitivity to the drug;

Coronary heart disease (angina pectoris);

Arterial hypertension;

Chronic heart failure;

Thyrotoxicosis;

Pheochromocytoma;

Angle-closure glaucoma;

Prostatic hyperplasia (in the presence of residual urine);

Insomnia;

Children under 3 years of age;

First trimester of pregnancy;

Breast-feeding;

Fructose intolerance and glucose/galactose malabsorption syndrome or sucrase/isomaltase deficiency (each dose of the drug (5 ml) contains up to 2 g of sucrose).

Carefully:

prescribed to patients prone to developing drug dependence. Due to the ethanol content of the drug, caution should be exercised when prescribing the drug to patients with liver disease, chronic alcoholism, epilepsy, brain diseases, children and pregnancy (II-III trimester).

Use during pregnancy and lactation

Do not use in the first three months of pregnancy and during breastfeeding.

Directions for use and doses Broncholitin® syrup

Inside, after eating.

Adults and children over 10 years old: 10 ml 3-4 times a day.

Children from 3-10 years:5 ml 3 times a day.

Duration of treatment: 5-7 days.

Side effect

The following adverse drug reactions may occur:

Cardiovascular system - heart rhythm and conduction disturbances, tachycardia, increased blood pressure;

Central nervous system (CNS) - tremor, dizziness, agitation, insomnia;

Gastrointestinal tract - loss of appetite, nausea, vomiting, constipation;

Urinary system - difficulty urinating; in patients with prostatic hyperplasia, urinary retention is possible;

Sense organs - visual impairment;

Others - tachyphylaxis, increased sweating;

Allergic reactions - urticaria, bronchospasm.

Overdose

Symptoms: nausea, vomiting, loss of appetite, nervous agitation, tremors of the limbs, dizziness, difficulty urinating, increased blood pressure.

Treatment: gastric lavage, use of activated carbon and symptomatic treatment.

Interaction with other drugs

When used simultaneously with cardiac glycosides, some sympathomimetics, agents for inhalation anesthesia (halothane), quinidine, tricyclic antidepressants, there is a risk of developing arrhythmias. Similar effects can be observed when used simultaneously with oxytocin or with drugs containing ergot alkaloids.

Monoamine oxidase inhibitors (MAO) potentiate the vasoconstrictor effect of ephedrine (risk of hypertensive crises with simultaneous use).

Taking the drug Bronholitin® is possible only 2 weeks after stopping taking MAO inhibitors. Reduces the hypotensive effect of sympatholytics due to the sympathomimetic effect of ephedrine.

When used together with non-selective β-blockers, the bronchodilator effect of the drug is reduced.

When taken simultaneously with oral hypoglycemic agents, the hypoglycemic effect may be reduced.

Drugs that stimulate the central nervous system (CNS) or herbal tonic drinks (coffee, tea, Coca-Cola) may enhance the stimulating effects of Broncholitin® on the central nervous system.

special instructions

Due to the stimulating effect on the central nervous system and possible sleep disturbance, it is not recommended to take Broncholitin® after 16 hours.

If, 5-7 days after the start of treatment, symptoms of the disease persist or the condition worsens, you should consult your doctor.

The drug contains methyl and propyl parahydroxybenzoate as an excipient, which, although rarely, can cause urticaria, as well as an immediate hypersensitivity reaction with bronchospasm.

Due to the possible occurrence of dizziness and visual impairment, caution should be exercised when performing work that requires increased attention and speed of psychomotor reactions, incl. when driving a car and working with machinery.

Release form Bronholitin®

Syrup.

125 g of the drug in dark glass bottles, sealed with aluminum caps or Pilfer-Proof polyethylene caps or in dark polyethylene terephthalate bottles (with a recess on the bottom of the bottle), sealed with Pilfer-Proof polyethylene caps. Each bottle, along with a measuring spoon (5 ml) or measuring cup (20 ml) and instructions for use, is placed in a cardboard box.

Storage conditions

In this article you can read the instructions for use of the drug Bronholitin. Reviews of site visitors - consumers of this medicine, as well as the opinions of specialist doctors on the use of Broncholitin in their practice are presented. We kindly ask you to actively add your reviews about the drug: whether the medicine helped or did not help get rid of the disease, what complications and side effects were observed, perhaps not stated by the manufacturer in the annotation. Analogues of Broncholitin in the presence of existing structural analogues. Use for the treatment of dry cough in adults, children, as well as during pregnancy and breastfeeding. Composition of the drug.

Bronholitin- a combined drug with antitussive and bronchodilator effects.

Glaucine hydrobromide suppresses the cough center without leading to respiratory depression, constipation or drug dependence.

Ephedrine dilates the bronchi, stimulates breathing and, due to its vasoconstrictor effect, eliminates swelling of the bronchial mucosa.

Basil oil has a slight sedative, antimicrobial and antispasmodic effect.

Compound

Glaucine hydrobromide + Ephedrine hydrochloride + excipients.

Pharmacokinetics

After oral administration, glaucine hydrobromide and ephedrine hydrochloride are quickly and well absorbed from the gastrointestinal tract. Glaucine hydrobromide is metabolized in the liver and excreted primarily in the urine. Ephedrine hydrochloride is excreted unchanged in the urine.

Indications

As part of complex therapy for various respiratory diseases accompanied by dry cough, including:

• acute inflammatory diseases of the upper respiratory tract;
• acute and chronic bronchitis;
• tracheobronchitis;
• COPD;
• bronchial asthma;
• pneumonia;
• bronchiectasis;
• whooping cough

Release forms

Other forms, such as tablets, do not exist at the time the drug was described in the reference book.

Instructions for use and dosage

Adults are prescribed 10 ml 3-4 times a day.

Children aged 3 to 10 years - 5 ml 3 times a day; children over 10 years old - 10 ml 3 times a day.

Side effect

• tachycardia;
• extrasystole;
• increased blood pressure;
• tremor;
• excitation;
• insomnia;
• dizziness;
• drowsiness;
• visual impairment;
• nausea, vomiting;
• anorexia;
• constipation;
• increased libido;
• dysmenorrhea;
• difficulty urinating;
• urinary retention in patients with prostatic hyperplasia;
• rash;
• increased sweating.

Contraindications

• arterial hypertension;
• severe organic heart disease;
• heart failure;
• pheochromocytoma;
• thyrotoxicosis;
• insomnia;
• angle-closure glaucoma;
• prostatic hyperplasia with clinical manifestations;
• 1st trimester of pregnancy;
• lactation period (breastfeeding);
• children under 3 years of age;
• hypersensitivity to the components of the drug.

Use during pregnancy and breastfeeding

The drug is contraindicated for use in the 1st trimester of pregnancy and during lactation (breastfeeding).

During other periods of pregnancy, the drug should be prescribed with caution.

special instructions

When using the drug Bronholitin, it is necessary to take into account that 1 measuring spoon or 1 glass (5 ml) contains up to 0.069 g of ethanol (alcohol) 96%.

The drug is available by prescription as it contains narcotic substances and their derivatives (ephedrine). In therapeutic dosages, the drug is safe and non-addictive.

Impact on the ability to drive vehicles and operate machinery

Due to the possible occurrence of dizziness and visual impairment, caution should be exercised when performing work that requires increased attention and speed of psychomotor reactions, incl. when driving a car and working with machinery.

Drug interactions

Bronholitin can be used simultaneously with antibiotics, antipyretics and vitamins.

Ephedrine, which is part of the drug, weakens the effect of opioid analgesics and hypnotics.

When using ephedrine simultaneously with cardiac glycosides, quinidine, and tricyclic antidepressants, the risk of developing arrhythmias increases.

With the simultaneous use of ephedrine with reserpine and MAO inhibitors, a sharp increase in blood pressure is possible.

With simultaneous use of ephedrine with non-selective beta-blockers, the bronchodilator effect may be reduced.

There is no data on drug interactions between glaucine and other drugs.

Analogs of the drug Bronholitin

Structural analogues of the active substance:

• Bronchitusen Vramed;
• Bronchoton;
• Bronchocin.

If there are no analogues of the drug for the active substance, you can follow the links below to the diseases for which the corresponding drug helps, and look at the available analogues for the therapeutic effect.

R.05.D.B Other antitussives

R.05.D.B.20 Combination drugs

Broncholitin is a combined syrup with antitussive, bronchoantiseptic and bronchodilator effects.

Active ingredients – Glaucine + Ephedrine. Auxiliary components: anhydrous citric acid, basil oil, ethanol 96% (1.7%), sucrose, methyl parahydroxybenzoate (nipagin), propyl parahydroxybenzoate (nipazole), polysorbate 80, purified water.

The complex effect of the drug is due to the properties of its main components: glaucine hydrobromide and ephedrine hydrochloride.

Glaucine inhibits the cough center without having a depressing effect on the respiratory center. It has a mild analgesic, bronchospasmolytic and anti-inflammatory effect.

Ephedrine is a mixed-action sympathomimetic that excites α- and β-adrenergic receptors and causes the release of norepinephrine from the depot. Moderately inhibits MAO activity. Reduces swelling of the bronchial mucosa, causes constriction of arterioles and increases blood pressure. Improves atrioventricular conduction and enhances cardiac activity. Activates excitation processes in the central nervous system, stimulates the respiratory center.

Bronholitin syrup can reduce the spastic effect of histamine on the bronchi. And thanks to the bronchodilating effect of ephedrine, bronchial obstruction is reduced and sputum separation occurs more easily.

Basil oil, which is contained in the syrup, provides an anesthetic, anti-inflammatory, sedative, and also a mild antiseptic effect.

Indications for use

What does Bronholitin help with? According to the instructions, the syrup is prescribed as part of complex therapy for various respiratory diseases accompanied by dry cough, including:

• acute inflammatory diseases of the upper respiratory tract;
• acute and chronic bronchitis;
• tracheobronchitis;
• COPD;
• bronchial asthma;
• pneumonia;
• bronchiectasis;
• whooping cough

Instructions for use Bronholitin, syrup dosage

The syrup is taken orally after meals. The standard dosage, according to the instructions for use of Broncholitin syrup, depends on age:

• children from 3 to 10 years old - 5 ml of syrup \ 3 times a day;
• children over 10 years old – 10 ml \ 3 times a day;
• adults – 10 ml \ 3-4 times a day.

Duration of treatment: 5-7 days. If the drug is ineffective, a revision of the diagnosis and a change in the treatment regimen is required.

special instructions

When using Bronholitin, it should be taken into account that 5 ml of syrup (1 measuring spoon or 1 glass) contains up to 0.069 g of ethanol 96% (1.7 vol.%).

The syrup can be used in conjunction with antibacterial drugs, vitamin and mineral complexes, and antipyretics.

Side effects

The instructions warn about the possibility of developing the following side effects when prescribing Bronholitin:

• disturbance of cardiac rhythm conduction;
• increased blood pressure;
• agitation, tremor, dizziness, insomnia;
• nausea, anorexia, constipation, vomiting;
• difficulty urinating;
• skin rash, urticaria, itching, increased sweating;
• visual impairment;
• allergic reactions;
• bronchospasm;
• tachyphylaxis;
• angioedema.

Contraindications

It is contraindicated to prescribe Bronholitin in the following cases:

• hypersensitivity to the components of the drug;
• arterial hypertension;
• severe organic heart disease;
• cardiac ischemia;
• glaucoma;
• children under 3 years of age;
• pheochromocytoma;
• prostatic hypertrophy with urinary retention;
• thyrotoxicosis;
• insomnia;
• pregnancy (first trimester) and lactation period.

Overdose

Symptoms of overdose are vomiting, nausea, agitation, loss of appetite, difficulty urinating, tremors of the limbs, poor circulation, sweating and dizziness.

Analogues of Bronholitin syrup, price in pharmacies

If necessary, you can replace Bronholitin with an analogue of the active substance - these are the following drugs:

1. Bronchoton (from RUB 31.00),
2. Bronchitusen Vramed (from 70.00 rubles),
3. Bronchosevt,
4. Bronchocin.

Similar in action:

• Kodipront,
• Tedein,
• Tussin plus,
• Terkodin,
• Alex Plus,
• Glycodin.

When choosing analogues, it is important to understand that the instructions for use of Broncholitin syrup, price and reviews do not apply to drugs with similar effects. It is important to consult a doctor and not change the drug yourself.

Price in Russian pharmacies: Broncholitin syrup 125g - from 76 to 129 rubles, according to 613 pharmacies.

Store out of the reach of children, at temperatures up to 25 °C. The drug should not be frozen. Shelf life – 4 years. After opening the bottle, the drug can be used for 30 days.

Dispensing conditions from pharmacies are by prescription.

In 5 ml of syrup: active substances glaucine hydrobromide (glaucine hydrobromide) 5.75 mg and ephedrine hydrochloride (ephedrine hydrochloride) 4.6 mg.

Excipients: basil oil, citric acid monohydrate, methyl parahydroxybenzoate, propyl parahydroxybenzoate, polysorbate 80, sucrose, ethyl alcohol 96%, purified water

Description

Yellow-brown syrupy liquid with a specific odor of basil oil

Pharmacotherapeutic group

Medicines to relieve symptoms of colds and coughs. Other antitussives. Combination drugs

ATX code R05DB20

Pharmacological properties

Pharmacokinetics

Absorption: After oral administration, glaucine hydrobromide and ephedrine hydrochloride are quickly and completely absorbed from the gastrointestinal tract.

Distribution: the maximum plasma concentration of glaucine hydrobromide is achieved 1.5 hours after its administration.

Ephedrine hydrochloride is distributed in the body with accumulation mainly in the liver, lungs, kidneys, spleen and brain.

Metabolism: Glaucine hydrobromide and ephedrine hydrochloride (small part) are metabolized in the liver.

Excretion: glaucine hydrobromide is excreted in the urine in the form of metabolites and unchanged.

The half-life of ephedrine hydrochloride is approximately 3-6 hours. It is excreted in urine mainly unchanged.

Pharmacodynamics

Broncholitin® is a combined drug with antitussive, bronchodilator and bronchoantiseptic effects.

The alkaloid glaucine inhibits the cough center without affecting breathing. It has a mild bronchospasmolytic and adrenolytic effect and does not cause addiction or dependence.

Ephedrine hydrochloride is an adrenomimetic of direct (stimulates alpha and beta receptors) and indirect (suppresses the activity of amino oxidase) action. Causes the release of norepinephrine and adrenaline from their depots. Ephedrine has an antispasmodic effect on the smooth muscles of the bronchi. It relaxes the bronchial muscles for a long time, which is caused by a pronounced stimulating effect on beta2-adrenergic receptors. Under the influence of ephedrine, swelling of the bronchial mucosa decreases and their lumen expands. Pharmacological studies of Bronholitin® syrup show that it reduces the spastic effect of histamine on the bronchi.

Indications for use

It is used in the complex treatment of inflammatory diseases of the respiratory tract.

Directions for use and doses

The syrup is taken orally after meals.

Adults and children over 10 years of age: 10 ml 3-4 times a day.

Children from 3 to 10 years of age: 5 ml 3 times a day.

Duration of treatment: 5-7 days.

Side effects

When treated with Bronholitin®, the following side effects are possible:

From the cardiovascular system - cardiac rhythm and conduction disturbances, increased blood pressure, myocardial ischemia (with unknown frequency)

From the nervous system – tremor, dizziness, agitation, insomnia

From the gastrointestinal tract – loss of appetite, nausea, vomiting, constipation

From the kidneys and urinary tract - difficulty urinating, urinary retention in patients with prostatic hypertrophy

From the skin and subcutaneous tissues - rashes, increased sweating, allergic reactions

From the organ of vision – visual impairment (mydriasis)

Others - tachyphylaxis

Contraindications

Hypersensitivity to active or excipients of the drug

Cardiac ischemia

Arterial hypertension

Severe organic heart disease with manifestations of decompensation

Thyrotoxicosis

Pheochromocytoma

Glaucoma

Prostatic hypertrophy with urinary retention

Insomnia

Children under 3 years of age

First trimester of pregnancy

Lactation period

Congenital fructose intolerance, glucose-galactose malabsorption syndrome or sucrase-isomaltase deficiency

Drug interactions

When used simultaneously with cardiac glycosides, some sympathomimetics, halogenated anesthetics (halothane), quinidine, tricyclic antidepressants, there is a risk of cardiac arrhythmia. Similar effects can be observed when used simultaneously with ergoalkaloids or oxytocin.

MAO inhibitors potentiate the pressor effect of ephedrine (risk of hypertensive crises with simultaneous use). If treatment with Broncholitin is necessary, a two-week interval should be observed after stopping the use of monoamine oxidase inhibitors.

When used simultaneously with non-selective β-blockers, the bronchodilator effect of the drug is reduced.

Sympathomimetics antagonize the antihypertensive effects of beta blockers.

With simultaneous treatment with Broncholitin and oral antidiabetic drugs, their hypoglycemic effect may be reduced.

Other CNS-stimulating drugs or herbal tonic drinks (coffee, tea, Coca-Cola) may enhance the stimulating effects of Broncholitin on the central nervous system when used simultaneously.

special instructions

Due to the stimulating effect on the central nervous system and possible sleep disturbance, it is not recommended to take Broncholitin® after 16:00 pm.

Patients prone to developing drug dependence should use the drug with caution.

If, after 5-7 days from the start of treatment, symptoms continue or the condition worsens, treatment should be reconsidered.

When treated with sympathomimetics, including Broncholitin, cardiovascular effects can be observed. Data from post-marketing studies and the published literature provide known evidence of rare cases of myocardial ischemia associated with the use of beta-agonists (ephedrine hydrochloride). Patients with heart disease (coronary artery disease, arrhythmia, or heart failure) who are using this drug should seek medical attention if they experience chest pain or other symptoms of worsening heart disease. Particular attention should be paid to assessing symptoms such as dyspnea and chest pain, as they can be of either respiratory or cardiac origin.

Bronholitin® contains up to 1.7 vol.% ethanol. A dose of 5 ml of syrup contains up to 69 mg of alcohol. Harmful for those suffering from alcoholism. The alcohol content should be considered when used by pregnant and breastfeeding women, children and high-risk groups such as patients with liver disease or epilepsy.

The drug contains 43.75 g of sucrose. When used according to dosage recommendations, up to 2 g of sucrose is delivered to the body with each 5 ml dose. Not suitable for persons with impaired absorption of sugars (congenital fructose intolerance, glucose-galactose malabsorption syndrome or sucrase-isomaltase deficiency).

The syrup contains methyl and propyl parahydroxybenzoate as excipients, which can cause allergic reactions (possibly delayed).

Pregnancy and lactation

Not used in the first three months of pregnancy and during breastfeeding.